Are you a Healthcare Professional or a Patient or Care Partner?
aFollowing the starting dose. Day 1 infusion is 150 mg over 4 hours; Day 15 infusion is 450 mg over 1 hour; subsequent infusions are 450 mg over 1 hour, every 24 weeks.
bARR for BRIUMVI observed in the ULTIMATE I and II identical 2-year Phase 3 trials with 543 patients treated with BRIUMVI and 546 treated with teriflunomide. The ARR for Study 1: 0.076 for BRIUMVI vs 0.188 for teriflunomide (P<0.001) and for Study 2: 0.091 for BRIUMVI vs 0.178 for teriflunomide (P=0.002).
ARR, annualized relapse rate.
aFollowing the starting dose. Day 1 infusion is 150 mg over 4 hours; Day 15 infusion is 450 mg over 1 hour; subsequent infusions are 450 mg over 1 hour, every 24 weeks.
bARR for BRIUMVI observed in the ULTIMATE I and II identical 2-year Phase 3 trials with 543 patients treated with BRIUMVI and 546 treated with teriflunomide. The ARR for Study 1: 0.076 for BRIUMVI vs 0.188 for teriflunomide (P<0.001) and for Study 2: 0.091 for BRIUMVI vs 0.178 for teriflunomide (P=0.002).
ARR, annualized relapse rate.
aFollowing the starting dose. Day 1 infusion is 150 mg over 4 hours; Day 15 infusion is 450 mg over 1 hour; subsequent infusions are 450 mg over 1 hour, every 24 weeks.
bARR for BRIUMVI observed in the ULTIMATE I and II identical 2-year Phase 3 trials with 543 patients treated with BRIUMVI and 546 treated with teriflunomide. The ARR for Study 1: 0.076 for BRIUMVI vs 0.188 for teriflunomide (P<0.001) and for Study 2: 0.091 for BRIUMVI vs 0.178 for teriflunomide (P=0.002).
ARR, annualized relapse rate.
aFollowing the starting dose. Day 1 infusion is 150 mg over 4 hours; Day 15 infusion is 450 mg over 1 hour; subsequent infusions are 450 mg over 1 hour, every 24 weeks.
bARR for BRIUMVI observed in the ULTIMATE I and II identical 2-year Phase 3 trials with 543 patients treated with BRIUMVI and 546 treated with teriflunomide. The ARR for Study 1: 0.076 for BRIUMVI vs 0.188 for teriflunomide (P<0.001) and for Study 2: 0.091 for BRIUMVI vs 0.178 for teriflunomide (P=0.002).
ARR, annualized relapse rate.
BRIUMVI is the first and only anti-CD20 therapy to achieve an ARR of less than 0.1 in two phase 3 trials.2,3,b
BRIUMVI is the first and only anti-CD20 therapy to achieve an ARR of less than 0.1 in two phase 3 trials.2,3,b
than 0.1 in two phase 3 trials.
BRIUMVI is glycoengineered to exclude certain sugar molecules that allows for tighter binding to NK cells with the goal of efficient B-cell depletion.2,3
The precise mechanism by which BRIUMVI exerts its therapeutic effects is unknown.2
BRIUMVI is the first and only anti-CD20 therapy to achieve an ARR of less than 0.1 in two phase 3 trials.2,3,b BRIUMVI is the first and only anti-CD20 therapy to achieve an ARR of less than 0.1 in two phase 3 trials.
BRIUMVI is glycoengineered to exclude certain sugar molecules that allows for tighter binding to NK cells with the goal of efficient B-cell depletion.2,3
The precise mechanism by which BRIUMVI exerts its therapeutic effects is unknown.2
BRIUMVI is the first and only anti-CD20 therapy to achieve an ARR of less than 0.1 in two phase 3 trials.2,3,b BRIUMVI is the first and only anti-CD20 therapy to achieve an ARR of less than 0.1 in two phase 3 trials. BRIUMVI is the first and only anti-CD20 therapy to achieve an ARR
BRIUMVI is glycoengineered to exclude certain sugar molecules that allows for tighter binding to NK cells with the goal of efficient B-cell depletion.2,3
The precise mechanism by which BRIUMVI exerts its therapeutic effects is unknown.2
The only anti-CD20 therapy that is administered as a 1-hour infusion, twice per year following the starting dose.2,a
The only anti-CD20 therapy that is administered as a 1-hour infusion, twice per year. The only anti-CD20 therapy that is The only anti-CD20 therapy that is
The most common adverse reactions in two phase 3 clinical trials were infusion reactions and upper respiratory tract infections.2 Overall infection rates across both arms were similar for BRIUMVI (56%) and teriflunomide (54%). The infections were predominantly mild to moderate in severity.2
The only anti-CD20 therapy that is administered as a 1-hour infusion, twice per year following the starting dose.2,a
The only anti-CD20 therapy that is administered as a 1-hour infusion, twice per year. The only anti-CD20 therapy that is The only anti-CD20 therapy that is
The most common adverse reactions in two phase 3 clinical trials were infusion reactions and upper respiratory tract infections.2 Overall infection rates across both arms were similar for BRIUMVI (56%) and teriflunomide (54%). The infections were predominantly mild to moderate in severity.2
BRIUMVI Patient Support offers dedicated case managers, insurance support and financial assistance options for eligible patients
References: 1. Data on File, TG Therapeutics 2024. 2. BRIUMVI Prescribing information. TG Therapeutics Inc; 2022. 3. Steinman L, Fox E, Hartung H-P, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387(8):704-714. doi:10.1056/NEJMoa2201904.
Are you a Healthcare Professional or a Patient or Care Partner?